UNSPSC 51413911: Vincantril

This classification denotes a vasodilating agent with the molecular formula C14H13ClN2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S0KXB0NKWN, chemically known as 10-chloro-1,2,3,3a,4,5-hexahydro-6h-indolo(3,2,1-de)(1,5)naphthyridin-6-one but generally known as vincantril, which bears US NIH Compound Identifier 68854. European Medicines Agency schedules Vincantril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00056MIG. The term VINCANTRIL is an International Non-Proprietary Name.

UNSPSC 51413911 Vincantril, a Commodity code, covers branded and specialty pharmaceutical products that state and local governments procure for emergency medical services, public health programs, and institutional healthcare delivery. State and local agencies buy specific medications under this code through competitive sealed-bid and cooperative purchasing channels, with recent solicitations reflecting demand for life-support medications, therapeutic pharmaceuticals, and over-the-counter products supplied through established wholesaler networks. Issuing bodies include city fire departments (Tampa Fire Rescue via the City of Tampa), state health commissions (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance), with cooperative vehicles enabling participation across multiple jurisdictions and state facilities simultaneously.

Activity under the code is geographically distributed across the South, Midwest, and nationwide through cooperative structures. Recent solicitations include the City of Tampa's sealed-bid procurement for Advanced Life Support Medications (Solicitation 26P00188, due April 8, 2026, estimated contract value $40,000.00) requiring 370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials for Tampa Fire Rescue, with a one-year contract term plus two optional renewals; the Texas Health and Human Services Commission's Request for Information (RFI HHS0017013, posted April 3, 2026) exploring direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements; and the Minnesota Department of Administration's MMCAP Request for Proposal (S1070000015802, due March 26, 2026) establishing multiple-award contracts for generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon, with awarded vendors effective July 1, 2026, and contract terms extending through June 30, 2028 for incumbents. Vendors must comply with FDA requirements, cGMP and DSCSA certification, nine to twelve-month minimum expiration dating, OSHA hazard communication standards, and substantial liability insurance ($2–5 million per occurrence depending on coverage type).